Patrik Andersson, PhDRNA Therapeutics Safety Lead at AstraZeneca
Agenda Sessions
RNA Therapeutics Safety
On DemandView SessionSafety Issues Related to Chemically Modified Oligos and Conjugates
16:30View Session